Century Therapeutics(IPSC)
icon
搜索文档
What Makes Century Therapeutics (IPSC) a New Buy Stock
ZACKS· 2024-11-09 02:01
Century Therapeutics, Inc. (IPSC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked ...
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
ZACKS· 2024-11-06 00:16
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.57%. A quarter ago, it was expected that this company would post a loss of $0.50 per share when it actually produced a loss of $0.38, delivering a surprise of 24%.Over the last four quarters, the company has ...
Century Therapeutics(IPSC) - 2024 Q3 - Quarterly Results
2024-11-05 22:10
Exhibit 99.1 Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates – Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include dif use cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study – – CNTY-101 shows persistence upon repeated cell dosing at Dose Level ...
Century Therapeutics(IPSC) - 2024 Q3 - Quarterly Report
2024-11-05 22:05
Table of Contents | --- | --- | |--------------------------------------------------------------------|------------| | UNITED STATES SECURITIES AND EXCHANGE WASHINGTON, DC 20549 | COMMISSION | | FORM 10-Q | | (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commissio ...
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire News Room· 2024-11-05 22:05
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy –– Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study –– CNTY-101 shows persistence upon repeated cell dosing at Dose Level 3B, consistent with the anticipated protective activity of Century’s proprietary Allo-Evasion™ technology –– E ...
Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference
GlobeNewswire News Room· 2024-11-04 20:00
PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:30am ET. A live webc ...
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
ZACKS· 2024-08-08 21:50
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 24%. A quarter ago, it was expected that this company would post a loss of $0.50 per share when it actually produced a loss of $0.45, delivering a surprise of 10%. Over the last four quarters, the company has s ...
Century Therapeutics(IPSC) - 2024 Q2 - Quarterly Results
2024-08-08 19:37
临床试验进展 - 公司完成了CNTY-101在系统性红斑狼疮(SLE)的CALiPSO-1临床1期试验的启动,标志着公司向自身免疫疾病领域的战略性扩展[2] - 公司在ASCO会议上展示了CNTY-101在复发/难治性CD19阳性B细胞淋巴瘤患者中的中期临床试验结果,显示出令人鼓舞的初步疗效和耐受性数据[3] - 公司完成了ELiPSE-1临床试验的剂量递增阶段,并预计在2024年下半年进入剂量扩展阶段[10] - 公司修订了CALiPSO-1临床试验方案,新增了狼疮肾炎(LN)患者的专门队列[7] 财务状况 - 公司于2024年6月30日的现金、现金等价物和投资总额为2.696亿美元,预计可维持运营至2026年[12] - 公司2024年第二季度的研发费用为2720万美元,较2023年同期增加20%,主要由于CNTY-101的生产活动增加和收购Clade Therapeutics公司[14] - 公司预计2024年全年GAAP经营费用将在1.5亿美元至1.6亿美元之间[17] - 公司完成了6000万美元的股权私募融资,并完成了对Clade Therapeutics公司的收购[11] - 公司2024年第二季度的合作收入为80万美元,较2023年同期增加[13] - 公司2024年第二季度的净亏损为3120万美元,较2023年同期有所下降[16] - 2024年第二季度合作收入为7.71亿美元,较2023年同期增长680.81%[27] - 2024年上半年合作收入为16.25亿美元,较2023年同期下降10.67%[27] - 2024年第二季度研发费用为2.722亿美元,较2023年同期增长19.65%[28] - 2024年上半年研发费用为5.064亿美元,较2023年同期增长6.32%[28] - 2024年第二季度营业亏损为3.476亿美元,较2023年同期减亏0.92%[29] - 2024年上半年营业亏损为6.607亿美元,较2023年同期减亏1.62%[29] - 2024年第二季度净亏损为3.121亿美元,较2023年同期减亏6.27%[30] - 2024年上半年净亏损为5.927亿美元,较2023年同期减亏8.16%[30] - 2024年第二季度每股基本和稀释亏损为0.38美元,较2023年同期减亏32.14%[32] - 2024年上半年每股基本和稀释亏损为0.82美元,较2023年同期减亏25.45%[32]
Century Therapeutics(IPSC) - 2024 Q2 - Quarterly Report
2024-08-08 19:30
细胞疗法产品开发 - 公司正在开发基于成人干细胞的细胞疗法产品,用于治疗癌症和自身免疫性疾病[188] - 公司拥有行业领先的诱导多能干细胞(iPSC)技术和基因编辑能力,可以开发针对癌症和自身免疫性疾病的异基因细胞疗法[188,190] - 公司正在进行CNTY-101的ELiPSE-1临床试验,用于治疗复发或难治性CD19阳性B细胞恶性肿瘤,并已取得初步积极的临床数据[193] - 公司正在进行CNTY-101的CALiPSO-1临床试验,用于治疗中重度系统性红斑狼疮,并计划扩展至其他自身免疫性疾病[194] - 公司通过收购Clade Therapeutics公司,获得了新的技术和管线,进一步增强了其异基因细胞疗法平台[196] 战略合作与技术许可 - 公司与Bristol-Myers Squibb建立了战略合作关系,共同开发针对血液恶性肿瘤和实体瘤的自然杀伤细胞和T细胞疗法[200,201] - 公司与FCDI签署了许可协议,获得了制造和开发iPSC及其衍生细胞的相关技术[204,205,206] - 公司与FCDI签订全球许可协议,获得细胞分化和重编程相关专利权和技术的非独家许可,用于开发和商业化针对炎症和自身免疫疾病的iPSC衍生疗法[208] 财务状况 - 公司目前的现金和投资足以支持运营到2026年[199] - 公司未来可能需要通过股权融资等方式筹集更多资金,以支持产品研发和商业化[199] - 公司2024年第二季度研发费用为2,722万美元,较2023年同期增加4,493万美元,主要由于人员成本、实验室费用和合作费用的增加[231,232,233] - 公司2024年第二季度利息收入为358.2万美元,较2023年同期增加52.4万美元,主要由于平均现金和投资余额增加以及利率上升[236] - 公司2024年上半年研发费用为5.06亿美元,较2023年同期增加3,015万美元,主要由于实验室费用增加,但人员成本和设施费用有所下降[241,242] - 利息收入增加是由于现金、现金等价物和投资的平均余额获得的利率较高[245] - 公司自成立以来共筹集约6.66亿美元的净收益[246] - 公司于2024年6月30日拥有现金及现金等价物41.5百万美元和投资228.2百万美元[246] - 公司于2024年2月通过ATM融资发行了408.4502万股普通股,获得约1840万美元的总收益[247] - 公司于2024年4月完成了约6000万美元的PIPE融资[248] - 公司预计未来将继续亏损,需要寻求额外融资以支持研发和运营[249,250] - 公司2024年上半年经营活动产生的现金流出为5760万美元[252,253] - 公司2024年上半年投资活动产生的现金流出为2232.3万美元[255] - 公司2024年上半年筹资活动产生的现金流入为7489.2万美元[257] 未来展望 - 公司预计未来会继续增加研发投入,以推进管线产品的临床开发和商业化[197] - 公司目前主要收入来源于与Bristol-Myers Squibb的合作协议,未来几年内预计收入仍将主要来自该协议和其他潜在合作[212] - 研发费用主要用于iPSC细胞治疗平台技术和产品候选物的开发,未来预计会持续增加[218]
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Newsfilter· 2024-08-08 19:30
– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – – Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary efficacy and tolerability data in heavily pretreated relapsed/refractory – – Completed dose escalation for ELiPSE-1 and advancing into dose expansion in 2H 2024 – – Ended second quarter 2024 w ...